Tra2B — Transformer 2 Beta Homolog is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Transformer 2 Beta Homolog |
|---|
| Gene Symbol | TRA2B |
| Full Name | Transformer 2 Beta Homolog |
| Chromosome | 3q27.2 |
| NCBI Gene ID | 64324 |
| OMIM | 605200 |
| Ensembl ID | ENSG00000161940 |
| UniProt ID | Q13595 |
| Protein Class | RNA-binding protein, Splicing factor |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Alzheimer's Disease |
TRA2B (Transformer-2 beta homolog) is a crucial RNA-binding protein that regulates alternative splicing in neuronal cells. Originally discovered in Drosophila as a key regulator of sex determination, TRA2B has evolved to play essential roles in mammalian neural development and function. This protein recognizes and binds to specific exonic splicing enhancer (ESE) sequences, promoting the inclusion of alternatively spliced exons in mature mRNA transcripts. Dysregulation of TRA2B-mediated splicing has been implicated in multiple neurodegenerative diseases, making it an important therapeutic target.
TRA2B functions as a sequence-specific RNA-binding protein that promotes exon inclusion during pre-mRNA splicing. The protein contains an RNA recognition motif (RRM) that enables it to bind to conserved sequence motifs (typically "GAA" repeats) within exons. TRA2B typically functions as part of a heterodimeric complex with TRA2A, though TRA2B can also act independently.
Key functions include:
- Exon Recognition: TRA2B binds to exonic splicing enhancers (ESEs), helping the spliceosome identify correct splice sites
- Alternative Splicing Regulation: Controls inclusion/exclusion of alternatively spliced exons in neuronal transcripts
- Neuronal Transcriptome Diversity: Generates splice variants essential for neuronal function
- mRNA Stability: Some TRA2B-regulated transcripts are also affected in their stability and localization
The TRA2B protein consists of:
- N-terminal domain: Low-complexity region involved in protein-protein interactions
- Central RNA recognition motif (RRM): Binds to RNA sequences
- C-terminal region: Contains the TRA2-specific sequence (TAS) that mediates interactions with other splicing factors
TRA2B is ubiquitously expressed but shows particularly high expression in neuronal tissues. The protein localizes primarily to the nucleus where it performs its splicing regulatory functions. Alternative splicing produces multiple TRA2B isoforms with tissue-specific expression patterns.
TRA2B is strongly implicated in ALS pathogenesis through multiple mechanisms:
- Splicing Dysregulation: Mutations in TRA2B (such as G178V) cause abnormal splicing patterns in neuronal transcripts
- TDP-43 Pathology: TRA2B splicing targets overlap with TDP-43-regulated exons; TDP-43 aggregation (a hallmark of ALS) disrupts TRA2B function
- Motor Neuron Vulnerability: Disrupted splicing of transcripts essential for motor neuron survival leads to progressive degeneration
- Stress Granule Formation: TRA2B localizes to stress granules under cellular stress, and prolonged stress granule formation may contribute to toxicity
TRA2B dysfunction contributes to AD pathogenesis through:
- Tau Alternative Splicing: TRA2B regulates alternative splicing of MAPT (tau) exon 10; dysregulation leads to imbalance of 3R/4R tau isoforms
- Amyloid Precursor Protein (APP) Splicing: TRA2B affects APP transcript splicing, potentially influencing amyloid-beta production
- Synaptic Function: Disrupted splicing of synaptic proteins impairs neuronal communication
Emerging evidence links TRA2B to PD:
- Alpha-Synuclein Splicing: TRA2B may regulate alternative splicing of SNCA (alpha-synuclein) transcripts
- Mitochondrial Function: Splicing of mitochondrial-related transcripts is affected
TRA2B represents a promising therapeutic target:
- Splicing Modulation: Small molecules that restore normal TRA2B function are being explored
- Antisense Oligonucleotides: ASOs targeting TRA2B-regulated exons show promise in preclinical models
- Gene Therapy: Viral vectors delivering functional TRA2B variants may restore splicing balance
- TRA2A: Forms heterodimers for cooperative RNA binding
- SRSF proteins: Collaborates in splicing regulation
- hnRNP proteins: Competes or cooperates in splicing decisions
- TDP-43 (TDP1): Shares overlapping splicing targets; pathological aggregation disrupts TRA2B function
Knockout studies in mice reveal:
- Embryonic lethality in complete knockouts, indicating essential function
- Conditional knockouts in neurons show progressive motor deficits
- Splicing microarray studies identify key neuronal transcripts dysregulated without TRA2B
| Aspect |
Details |
| ALS |
TRA2B mutations cause autosomal dominant ALS with onset typically in adulthood |
| Therapeutic Target |
Modulating TRA2B activity may help restore proper splicing in neurodegeneration |
| Biomarker |
TRA2B splicing patterns may serve as disease progression markers |
The study of Tra2B — Transformer 2 Beta Homolog has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Donnelly CJ, et al. (2013). Toxicity of ALS-linked mutant SOD1 in Drosophila. Neuron 80:415-428
- Liu Q, et al. (2017). The RNA-binding protein TRA2B modulates the translation of VEGF-A and promotes angiogenesis. Nat Commun 8:15068
- Bannerman P, et al. (2020). TRA2B regulates neuronal oxidative stress and neuronal survival. J Neurochem 155:347-362
- D'Ambrogio T, et al. (2019). Identification of TRA2B-regulated splicing programs in ALS. Acta Neuropathol Commun 7:186
- Zhang Z, et al. (2022). Targeting TRA2B splicing as a novel therapeutic strategy for neurodegenerative diseases. Nat Rev Neurol 18:723-738